Effective Dose & ICRP Tissue Weighting Factors

Introduction

Effective dose is the single most useful—and most abused—number in radiation protection: it collapses the doses to every radiosensitive organ into one whole-body figure that indexes stochastic risk, but it was never meant to estimate the risk to any one patient. When a physicist says a chest CT is "about 7 millisievert," that number is an effective dose, and understanding what it does and does not mean is central to communicating radiation risk honestly.¹⁹

Effective dose exists to solve a real problem. Different examinations irradiate different organs by different amounts, so you cannot compare their risk by absorbed dose to any single tissue. Effective dose weights each organ's dose by that organ's contribution to overall radiation detriment and adds them up, producing a common currency in which a bone scan, a coronary CT, and an interventional procedure can be ranked. The weighting factors that make this possible are the tissue weighting factors of ICRP Publication 103.¹

This article explains how equivalent dose and effective dose are calculated, lists the current ICRP 103 tissue and radiation weighting factors, shows how they changed from the earlier ICRP 60 set, works a numerical example, and—most importantly—draws the line between legitimate uses of effective dose and the individual-risk estimates it cannot support. DRPS applies these concepts in its medical physicist consulting and radiation safety training work across Florida, Maryland, Virginia, Washington DC, California, and Nevada.

Topic Explanation

Three quantities, only one of them measured

Radiation protection uses a ladder of three dose quantities, and confusing them is the most common error in the field:

Absorbed dose (D) — energy deposited per unit mass, in gray (Gy). This is the physical quantity, directly measurable.
Equivalent dose (H_T) — absorbed dose in a tissue, weighted by a radiation weighting factor for the biological damage potential of the radiation type, in sievert (Sv).
Effective dose (E) — the sum of organ equivalent doses, each weighted by a tissue weighting factor for that organ's radiosensitivity, in sievert (Sv).

Only absorbed dose is measured. Equivalent and effective dose are calculated protection quantities built on committee-defined weighting factors, and that calculated, policy-laden character is the root of both their usefulness and their limits.¹¹⁰ For the biological effects these quantities are meant to manage, see our companion article on stochastic and deterministic radiation effects.

Why weight by tissue at all?

A gray of dose to the thyroid does not carry the same lifetime cancer risk as a gray to the lung or the red bone marrow, because organs differ in radiosensitivity, in the lethality of the cancers they develop, and in the years of life lost. ICRP distills these differences into a set of tissue weighting factors, w_T, that represent each tissue's fractional share of total stochastic detriment for a whole-body uniform exposure. By definition they sum to 1.0, so a uniform whole-body equivalent dose gives an equal effective dose.¹

Key Technical Principles

The two governing equations

Equivalent dose to a tissue is the absorbed dose summed over radiation types, each weighted by its radiation weighting factor w_R:

H_{T} = R \sum w_{R} D_{T, R}

Effective dose is the equivalent dose summed over tissues, each weighted by its tissue weighting factor w_T:

E = T \sum w_{T} H_{T} = T \sum w_{T} R \sum w_{R} D_{T, R}

Absorbed dose D is in gray; the weighting factors are dimensionless; and the sievert is used for both H_T and E to signal that they are protection quantities, not physical dose.¹

Radiation weighting factors (ICRP 103)

The radiation weighting factor accounts for the fact that densely ionizing radiation (alpha particles, neutrons) produces more biological damage per gray than sparsely ionizing radiation (photons, electrons):

Radiation type	w_R (ICRP 103)
Photons (all energies)	1
Electrons and muons	1
Protons and charged pions	2 (was 5 in ICRP 60)
Alpha particles, fission fragments, heavy ions	20
Neutrons	Continuous function of energy (peaks near 20 around ~1 MeV)

For the photon and electron radiation used in diagnostic imaging, w_R = 1, so equivalent dose in sievert is numerically equal to absorbed dose in gray. This is why, in a purely diagnostic X-ray context, organ equivalent dose and organ absorbed dose are the same number.¹

Tissue weighting factors: ICRP 103 versus ICRP 60

The tissue weighting factors are the heart of effective dose. The table below gives the current ICRP 103 values alongside the superseded ICRP 60 values, so the direction of change is visible.

Tissue	w_T (ICRP 60, 1990)	w_T (ICRP 103, 2007)	Change
Red bone marrow	0.12	0.12	—
Colon	0.12	0.12	—
Lung	0.12	0.12	—
Stomach	0.12	0.12	—
Breast	0.05	0.12	↑
Remainder tissues	0.05	0.12	↑
Gonads	0.20	0.08	↓
Bladder	0.05	0.04	↓
Esophagus	0.05	0.04	↓
Liver	0.05	0.04	↓
Thyroid	0.05	0.04	↓
Bone surface	0.01	0.01	—
Skin	0.01	0.01	—
Brain	(in remainder)	0.01	newly explicit
Salivary glands	(not listed)	0.01	newly added
Sum	1.00	1.00	—

The two headline changes: breast rose from 0.05 to 0.12 (reflecting updated breast-cancer risk data), and gonads fell from 0.20 to 0.08 (reflecting a lower estimate of heritable risk). Brain and salivary glands became individually weighted at 0.01.¹² Under ICRP 103, the "remainder tissues" is a set of 14 named tissues (13 applicable in either sex, because prostate and uterus/cervix are the sex-specific pair) that share the 0.12 weight through their mean dose.¹

A worked effective-dose calculation

Consider a hypothetical photon exposure (so w_R = 1 and H_T equals organ absorbed dose numerically) that deposits the following organ equivalent doses. The effective-dose contribution of each is w_T × H_T:

Tissue	H_T (mSv)	w_T	w_T · H_T (mSv)
Lung	8	0.12	0.96
Colon	7	0.12	0.84
Breast	6	0.12	0.72
Stomach	5	0.12	0.60
Red bone marrow	4	0.12	0.48
Thyroid	3	0.04	0.12
Gonads	2	0.08	0.16

Summing the last column:

E = T \sum w_{T} H_{T} = 0.96 + 0.84 + 0.72 + 0.60 + 0.48 + 0.12 + 0.16 \approx 3.9 mSv

The result—about 3.9 mSv—is a single number that can be compared across examinations. Notice that no organ received 3.9 mSv; effective dose is a weighted construct, not a dose anyone's tissue actually experienced.¹

Clinical Impact

What effective dose is good for

Used as intended, effective dose is genuinely valuable. It lets a department:

Compare and optimize protocols across modalities on one scale (see CT physics testing and protocol work).
Benchmark against population exposure. NCRP Report No. 160 put the average U.S. annual effective dose at about 6.2 mSv (2006 data), roughly half natural background (~3.1 mSv) and half medical (~3.0 mSv), with CT and nuclear medicine driving the medical share.⁴ NCRP Report No. 184 (2019) subsequently reported a 15–20% decline in per-capita medical dose.⁵
Communicate relative magnitude to patients and referrers ("about the same as a year of natural background").

Where it breaks down: individual risk

The temptation is to multiply a patient's effective dose by a risk coefficient and announce a number of cancers. This is where effective dose fails, and the failure is not subtle:

The weighting factors are sex- and age-averaged policy values, not individualized biology. A given effective dose implies different risk for a 5-year-old girl and a 70-year-old man.⁹
The uncertainty in E for a reference patient is about ±40%, and the derived cancer-risk estimate may be a factor of three higher or lower—more still for a specific individual.⁶
Effective dose was built for prospective radiation protection, not retrospective epidemiology or individual prognostication.⁹¹⁰

The professional consensus is explicit. The AAPM position statement on radiation risks from medical imaging holds that risks from doses below roughly 50 mSv in a single exposure (or 100 mSv over a short period) are too low to be detectable and may be nonexistent, and that predicting specific numbers of hypothetical cancers from such exposures should be discouraged.¹¹ ICRP's own 2021 guidance (Publication 147) concludes that effective dose "may be considered as an approximate indicator of possible risk," while best individual-risk estimates use organ absorbed doses with appropriate risk models.¹⁰ The point is not that effective dose is useless—there is a well-known critique arguing it is a "flawed concept," answered by ICRP authors defending its protection role—but that its job is comparison and control, not personal prognosis.⁷⁸

Where effective dose does not apply at all

Effective dose describes stochastic risk. It says nothing about deterministic effects (tissue reactions)—skin erythema, epilation, cataract, marrow depression—which depend on absorbed dose to the specific tissue and have thresholds. ICRP Publication 118 sets the eye-lens cataract threshold at an absorbed dose of about 0.5 Gy and the occupational lens equivalent-dose limit at 20 mSv/year averaged over five years; those are tissue-specific quantities, not effective dose.³ Interventional skin injuries, discussed in our fetal dose in medical imaging and occupational-dose articles, are likewise absorbed-dose phenomena.

Practical Optimization Tips

1. Use the right quantity for the question

Comparing protocols or benchmarking a department → effective dose is appropriate.
Estimating an individual's risk → use organ/tissue absorbed doses and age/sex-specific risk models, and communicate uncertainty.⁹¹⁰
Assessing a possible tissue reaction (skin, lens) → use absorbed dose to that tissue, not E.³

2. Cite the weighting-factor set you used

State whether doses are computed with ICRP 103 or the older ICRP 60 factors; the same exposure yields a different E under each. Software and registries do not always agree.²⁵

3. Don't over-report precision

Given the ±40% reference-patient uncertainty, reporting effective dose to three significant figures implies a precision that does not exist. Round appropriately.⁶

4. Translate carefully for patients

Prefer comparisons to natural background over absolute cancer counts. Frame benefit against risk, since the diagnostic benefit of an indicated exam almost always dominates the small stochastic risk.⁹¹¹

Common pitfalls to avoid

Calling effective dose a patient's risk. It is a protection quantity for a reference person.⁹
Mixing weighting-factor generations when comparing values across sources.²
Applying E to deterministic effects. Skin and lens injuries are absorbed-dose phenomena.³
Multiplying E by a risk coefficient to count cancers for one person or a small cohort.⁶¹¹
Treating equivalent dose as if it were needed for every situation—ICRP 147 notes it is not required as a separate protection quantity for tissue-reaction limits.¹⁰

Regulatory Considerations

Effective dose and the weighting factors behind it come from ICRP recommendations, which regulators then adopt into dose limits. The current scientific basis is ICRP Publication 103 (2007), which supplies the tissue and radiation weighting factors now in force and superseded ICRP Publication 60 (1990).¹² ICRP Publication 118 (2012) governs tissue reactions and set the revised eye-lens threshold and limit.³ Population-level context in the United States comes from NCRP Report No. 160 and its medical-exposure update NCRP Report No. 184.⁴⁵

U.S. occupational dose limits—the annual 50 mSv total effective dose equivalent, the 15 mSv lens limit, and organ/skin limits—are codified in 10 CFR Part 20 for NRC-licensed radioactive material and in the parallel state programs for X-ray machines; those limits are expressed in the effective-dose framework. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States, while Washington, DC and Delaware are regulated directly by the NRC for radioactive material. For the occupational limits themselves, see our articles on NRC occupational dose limits under Part 20 and occupational exposure monitoring. Whatever the jurisdiction, the medical physicist's job is to apply the correct quantity—and to resist pressure to convert a population protection number into an individual verdict.

Frequently Asked Questions (FAQs)

What is effective dose?

Effective dose (E) is a radiation protection quantity that combines the equivalent doses to all radiosensitive organs into a single whole-body number, weighting each organ by its relative contribution to stochastic (cancer and heritable) risk. It is expressed in sieverts (Sv). Effective dose lets you compare exposures with very different organ-dose distributions—for example a chest CT versus a bone scan—on a common scale.

What is the difference between absorbed dose, equivalent dose, and effective dose?

Absorbed dose (gray, Gy) is the energy deposited per unit mass. Equivalent dose (sievert, Sv) multiplies absorbed dose in a tissue by a radiation weighting factor that accounts for how damaging that radiation type is. Effective dose (sievert, Sv) sums the equivalent doses across organs, each multiplied by a tissue weighting factor that reflects that organ's radiosensitivity. Only absorbed dose is directly measured; the others are calculated.

What are the ICRP 103 tissue weighting factors?

In ICRP Publication 103 (2007), six tissue groups carry a weighting factor of 0.12 (red bone marrow, colon, lung, stomach, breast, and the remainder tissues), gonads carry 0.08, four tissues carry 0.04 (bladder, esophagus, liver, thyroid), and four carry 0.01 (bone surface, brain, salivary glands, skin). The factors sum to exactly 1.00.

How did the tissue weighting factors change from ICRP 60 to ICRP 103?

The two headline changes were breast, which rose from 0.05 to 0.12, and gonads, which fell from 0.20 to 0.08. Brain and salivary glands became explicitly weighted at 0.01. Among radiation weighting factors, protons dropped from 5 to 2 and the neutron factor became a continuous function of energy. These updates reflected newer epidemiology, particularly on breast-cancer and heritable risk.

Can effective dose tell me an individual patient's cancer risk?

No. Effective dose is a protection quantity computed for a sex-averaged, age-averaged reference person, using weighting factors that are policy judgments about population detriment. The uncertainty in E for a reference patient is on the order of ±40%, and individual risk depends strongly on age and sex. Professional bodies including the AAPM caution against converting an individual's effective dose into a specific predicted number of cancers.

Where does effective dose not apply at all?

Effective dose is designed for stochastic risk at low doses. It does not describe deterministic effects (tissue reactions) such as skin injury, cataract, or bone-marrow depression, which are governed by absorbed dose to the affected tissue. For example, the eye-lens cataract threshold is expressed as an absorbed dose (about 0.5 Gy), not as an effective dose.

What is the average person's annual effective dose?

NCRP Report No. 160 estimated the average annual effective dose in the United States at about 6.2 mSv (2006 data), split roughly evenly between natural background (~3.1 mSv) and medical exposure (~3.0 mSv). NCRP Report No. 184 (2019) later reported a decline of roughly 15–20% in per-capita medical dose.

Key Takeaways

Effective dose is a calculated whole-body index of stochastic risk, built from organ equivalent doses weighted by ICRP 103 tissue weighting factors, expressed in sieverts.
The ladder matters: absorbed dose (Gy, measured) → equivalent dose (Sv, ×w_R) → effective dose (Sv, ×w_T). Only the first is directly measured.
ICRP 103 w_T values sum to 1.00; the big shifts from ICRP 60 were breast (0.05→0.12) and gonads (0.20→0.08).
Effective dose is for comparison and control, not individual prognosis. Reference-patient uncertainty is ~±40%, and risk is strongly age- and sex-dependent.
It does not describe tissue reactions. Skin injury and cataract are absorbed-dose phenomena with thresholds (eye lens ~0.5 Gy).
The U.S. average annual effective dose is ~6.2 mSv, about half medical, with per-capita medical dose declining in the most recent NCRP update.

Conclusion

Effective dose earns its central place in radiation protection because it does one thing exceptionally well: it turns the sprawling, organ-by-organ reality of a radiation exposure into a single number that can be compared, optimized, and benchmarked. The tissue weighting factors of ICRP 103 are the machinery that makes that possible, and knowing them—along with how they shifted from ICRP 60—is basic literacy for anyone managing medical radiation.

But the same averaging that makes effective dose comparable is what makes it wrong for individual risk. It is a reference-person quantity, wrapped in ±40% uncertainty, blind to age and sex, and silent on deterministic injury. A physicist who understands this can use effective dose to drive genuine dose optimization while refusing to launder a population protection number into a personal cancer count. That discipline—right quantity, right question, honest uncertainty—is what separates defensible dose communication from misleading it.

How DRPS Can Help

Diagnostic Radiation Physics Services helps imaging facilities and radiation safety programs use dose quantities correctly. That work includes protocol dose optimization and effective-dose benchmarking, organ-dose estimation where individual risk questions arise, patient- and staff-facing radiation risk communication, and radiation safety training that grounds staff in the difference between absorbed, equivalent, and effective dose.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware. Good dose communication starts with using the right quantity for the question.

Related Resources

References

International Commission on Radiological Protection. ICRP Publication 103: The 2007 Recommendations of the International Commission on Radiological Protection. Annals of the ICRP. 2007;37(2-4). icrp.org
International Commission on Radiological Protection. ICRP Publication 60: 1990 Recommendations of the International Commission on Radiological Protection. Annals of the ICRP. 1991;21(1-3). icrp.org
International Commission on Radiological Protection. ICRP Publication 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs. Annals of the ICRP. 2012;41(1-2). icrp.org
National Council on Radiation Protection and Measurements. NCRP Report No. 160: Ionizing Radiation Exposure of the Population of the United States. 2009. ncrponline.org
National Council on Radiation Protection and Measurements. NCRP Report No. 184: Medical Radiation Exposure of Patients in the United States. 2019. ncrponline.org
Martin CJ. Effective dose: how should it be applied to medical exposures? British Journal of Radiology. 2007;80(956):639-647. doi:10.1259/bjr/25922439. PubMed
Brenner DJ. Effective dose: a flawed concept that could and should be replaced. British Journal of Radiology. 2008;81(967):521-523. doi:10.1259/bjr/22942198. PubMed
Dietze G, Harrison JD, Menzel HG. Effective dose: a flawed concept that could and should be replaced. Comments on a paper by D J Brenner. British Journal of Radiology. 2009;82(976):348-350. doi:10.1259/bjr/91937653. PubMed
McCollough CH, Christner JA, Kofler JM. How effective is effective dose as a predictor of radiation risk? American Journal of Roentgenology. 2010;194(4):890-896. doi:10.2214/AJR.09.4179. PubMed
Harrison JD, Balonov M, Bochud F, Martin CJ, Menzel HG, Smith-Bindman R, Ortiz-López P, Simmonds JR, Wakeford R. The use of dose quantities in radiological protection: ICRP Publication 147. Journal of Radiological Protection. 2021;41(2). doi:10.1088/1361-6498/abe548. PubMed
American Association of Physicists in Medicine. AAPM Position Statement on Radiation Risks from Medical Imaging Procedures (PP 25). aapm.org